Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$117.1MCash on Hand
28.7mo Cash Runway
2.7%Short Interest
$7.56Analyst Target (9)
Follow PRQR by emailGet an email when PRQR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PRQR, unsubscribe in one click. Privacy
📣 What PRQR Says Is Next
first half of 2027 · “ProQR is also continuing preparations for an investigator-initiated trial (IIT) in pediatric biliary atresia in China, with initial clinical data expected in the first half of 2027.”
Company press release, Nov 12, 2026 · SEC filing
mid-2027 · “Potentially registration-enabling Phase 2 program, subject to regulatory interactions, expected to start in mid-2027 with first interim analysis data expected by mid-2028 Other pipeline candidates”
Company press release, Nov 12, 2026 · SEC filing
first half of 2027 · “IIT in pediatric biliary atresia in China, with initiation and initial data targeted for the first half of 2027”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings ProQR furnished unaudited financial statements and a press release reporting Q3 and nine-month 2026 results. Cash and cash equivalents were €102,986 thousand at September 30, 2026, up from €92,413 thousand at year-end 2025, and total equity rose to €68,184 thousand from €49,374 thousand. Form 6-K · SEC filing · Press release
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: cash of €103.0 million at September 30, 2026, with runway into mid-2028, and a net loss of €12.4 million, or €0.09 per diluted share. R&D costs rose to €14.3 million. Initial AX-0811 Phase 1 target engagement data is expected in early January 2027. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
ProQR will present AX-0810 Phase 1 data at AASLD (Nov 5 and Nov 8, 2026) and at Nature's RNA at the Bench and Bedside V (Dec 9, 2026), including Cohort 3 data and 12-week follow-up. A Phase 1 study of AX-0811 in healthy volunteers is underway, with initial data expected in early January 2027. Form 6-K · SEC filing · Press release
Sep 23, 2026 ·
Leadership ProQR appointed Chris Hart, PhD, as Chief Data and AI Officer, most recently VP of Data Science and AI/ML at Eli Lilly, and Thomas Wolf, PhD, co-founder and CSO of Hugging Face, to its Board as strategic AI advisor. AX-0811 target engagement data expected early January 2027. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Clinical trial Announced first participant dosed in the Phase 1 study of AX-0811, an RNA editing oligonucleotide targeting NTCP for cholestatic liver diseases including biliary atresia. Form 6-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Reported Q2 2026 results: net loss of €8.7 million (€0.08 per diluted share), cash of €117.1 million supporting runway into mid-2028, after a roughly $59.2 million financing including a $50.0 million registered direct offering. AX-0810 showed up to 8-fold bile acid increase. Form 6-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings ProQR reported unaudited results for the three and six months ended June 30, 2026, with cash and cash equivalents of €117,125 thousand at June 30, 2026, up from €92,413 thousand at December 31, 2025, and total equity of €79,477 thousand. The full results are in an attached press release. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2022 · Phase 1/2 · Active Trial · A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Registry primary completion date, not a results date
Jan 2022 · Phase 2/3 · Active Trial · A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) Registry primary completion date, not a results date
Oct 2021 · Phase 1/2 · Results Expected · Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene Registry primary completion date, not a results date
Sep 2017 · Phase 1/2 · Results Expected · Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients Registry primary completion date, not a results date
Sep 2016 · Phase 1 · Results Expected · Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PRQR holds $117.1M in cash and short-term investments and burns about $12.3M/quarter from operations,
an estimated runway of 28.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:0 · Low
Cash runway 29 months
Shelf registration (F-3, Sep 2024) +10
Raised after last reported balance sheet (Jun 2026) -10
Share count 105,361,064 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-07-31 filed 2026-08-03
de Boer Daniel Anton
Purchase (P)
200,000
$1.77
500,000
2026-07-17 filed 2026-07-21
Filius Bart
Purchase (P)
150,000
$1.72
300,000
2026-07-09 filed 2026-07-13
de Boer Daniel Anton
Purchase (P)
150,000
$1.74
300,000
2026-07-07 filed 2026-07-08
de Boer Daniel Anton
Purchase (P)
150,000
$1.59
150,000
2026-06-02 filed 2026-06-03
Hinsch Gylvin Lykke
Option award (A)
14,495
–
–
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
Get the full PRQR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRQR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.